MRNA · Company research

Moderna, Inc.

2 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

ApprovalMRNAModerna2026

Moderna expects European regulators to decide on mRNA-1010 / mFLUSIVA for Seasonal influenza, adults during 2026 (no exact date yet). An approval lets the company start selling it in that market.

More details

Entry

mRNA-1010 (mFLUSIVA) ex-US approvals (EU/Canada/Australia) expected to begin · Regulatory approval

Drug

mRNA-1010 / mFLUSIVA

For

Seasonal influenza, adults

Stage

Under regulatory review

When

2026 · the company gave a window, not a day

Source note

Moderna Q2 2026 earnings release (Aug 2026). FDA approved mFLUSIVA on Aug 5, 2026 (adults 50+); the Aug 5 approval release reiterates mRNA-1010 is under review in the EU, Canada and Australia with additional submissions planned during 2026.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
MRNA headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsMRNAModernaH2 2026

Moderna expects to report results from its Registrational study (target enrollment reached) study of mRNA-3927 for Propionic acidemia (rare metabolic disease) in the second half of 2026 (no exact date yet). Registrational study (target enrollment reached) is a study designed to support approval.

More details

Entry

mRNA-3927 registrational data in propionic acidemia · Clinical trial results (readout / topline data)

Drug

mRNA-3927

For

Propionic acidemia (rare metabolic disease)

Stage

Registrational study (target enrollment reached) · a study designed to support approval

When

H2 2026 · the company gave a window, not a day

Source note

Moderna Q2 2026 press release: 'Moderna expects potential data in 2026' from the registrational propionic acidemia study; MMA program decision deferred until these data read out.

Checked

Checked by a person when it was added

Verify it

Source: accessnewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MRNA headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

Trial resultsMRNAModernaAug 19, 2026

Moderna reported results from its Phase 3 study of intismeran autogene (mRNA-4157) for Adjuvant melanoma on Aug 19, 2026. The study met its main goal.

More details

Entry

First positive Phase 3 readout for an mRNA cancer therapy · Clinical trial results (readout / topline data)

Drug

intismeran autogene (mRNA-4157)

For

Adjuvant melanoma

Stage

Phase 3 · the last stage before a drug can be approved

When

Aug 19, 2026

Source note

Moderna/Merck individualized neoantigen therapy (intismeran autogene) met its primary endpoint in adjuvant melanoma; MRNA had its best day on record.

Checked

Checked by a person when it was added

Verify it

Source: finance.yahoo.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MRNA headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsMRNAModernaJul 31, 2026

Moderna reported results from its Phase 3 study of mRNA-1403 for Norovirus vaccine on Jul 31, 2026. The study missed its main goal.

More details

Entry

Phase 3 norovirus vaccine mRNA-1403 missed early-success bar at interim · Clinical trial results (readout / topline data)

Drug

mRNA-1403

For

Norovirus vaccine

Stage

Phase 3 · the last stage before a drug can be approved

When

Jul 31, 2026

Source note

Moderna disclosed that the Phase 3 NOVA 301 study of mRNA-1403 failed to clear the statistical bar for early success at its interim analysis. The trial stays blinded while the company enrolls an additional cohort for a third season.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MRNA headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

FDA panelMRNAModernaJun 18, 2026

An FDA advisory panel voted in favor of Moderna’s mRNA-1010 (mFLUSIVA) for Seasonal influenza prevention in adults 50+ on Jun 18, 2026. The FDA usually follows the panel, but it makes the final call.

More details

Entry

FDA AdComm votes 9-0 in favor of mRNA-1010 flu vaccine benefit-risk · FDA advisory panel meeting (AdComm)

Drug

mRNA-1010 (mFLUSIVA)

For

Seasonal influenza prevention in adults 50+

Stage

Regulatory (BLA)

When

Jun 18, 2026

Source note

VRBPAC voted 9-0 that benefits outweigh risks for mRNA-1010 in adults 50-64 and again 9-0 in adults 65 and older. The vote set up the August 5 PDUFA decision.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
FDA advisory committee calendar ↗
MRNA headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsMRNAModernaNov 16, 2020

Moderna reported results from its Phase 3 study of mRNA-1273 (Spikevax) for COVID-19 prevention on Nov 16, 2020. The linked source has what the numbers showed.

More details

Entry

COVE Phase 3 interim: mRNA-1273 94.5% efficacy · Clinical trial results (readout / topline data)

Drug

mRNA-1273 (Spikevax)

For

COVID-19 prevention

Stage

Phase 3 · the last stage before a drug can be approved

When

Nov 16, 2020

Source note

First interim analysis of the Phase 3 COVE study of Moderna's COVID-19 vaccine.

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
MRNA headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to MRNA.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.